Photo of Michael C. Heinrich, M.D.

Michael C. Heinrich M.D.

    • Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.

Education

  • M.D., Johns Hopkins University School of Medicine, 0 1984
  • Residency:

    • Oregon Health & Science University, 1988
  • Fellowship:

    • Hematology/medical oncology, Oregon Health & Science University, 1991
  • Certifications:

    • American Board of Internal Medicine, (internal medicine) 1987

Memberships and associations

  • American Society of Clinical Oncology

Publications

  • "Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)" Journal of Clinical Oncology March 1 2006
  • "Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors" Molecular Cancer Therapeutics August 2012
  • "Primary extragastrointestinal stromal tumor of the pleura" American Journal of Surgical Pathology June 2010
  • "Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells" Journal of Clinical Investigation August 1994
  • "Molecular basis for treatment of gastrointestinal stromal tumours" European Journal of Cancer, Supplement March 2006
  • "Gastrointestinal Stromal Tumors. Molecular Markers and Genetic Subtypes" Hematology/Oncology Clinics of North America October 2013
  • "RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518" Blood April 1 2005
  • "BRAF in papillary thyroid carcinoma of ovary (struma ovarii)" American Journal of Surgical Pathology September 2007
  • "In reply [11]" Journal of Clinical Oncology August 1 2006
  • "Enhancing effects of co-transduction of both human erythropoietin receptor and c-kit cDNAs into hematopoietic stem/progenitor cells from cord blood on proliferation and differentiation of erythroid progenitors" Cytokines, Cellular and Molecular Therapy  2000
  • "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients" Clinical Cancer Research November 15 2014
  • "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia" Blood November 15 2005
  • "KIT Mutations are Common in Testicular Seminomas" American Journal of Pathology January 2004
  • "Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia" Clinical Cancer Research October 1 2005
  • "Clinical management of gastrointestinal stromal tumors" Human Pathology  2002
  • "Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus" Blood April 15 2006
  • "Familial gastrointestinal stromal tumor syndrome" Journal of Clinical Oncology April 20 2005
  • "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo" Blood May 1 2003
  • "Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1." Journal of Medical Genetics January 2007
  • "STI 571 inhibits the kinase activity of wild type and juxtamembrane C-kit mutants but not the exon 17 D816V mutation associated with mastocytosis" Blood  2000
  • "Imatinib targeting of KIT-mutant oncoprotein in melanoma" Clinical Cancer Research December 1 2008
  • "Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit" Bioorganic and Medicinal Chemistry May 1 2003
  • "A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib" Leukemia November 2005
  • "Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance" Journal of Cancer Research March 1 2015
  • "FLT3 K663Q is a novel AML-associated oncogenic kinase" Leukemia November 2006
  • "In response" American Journal of Surgical Pathology August 2011
  • "Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib- sensitivetyrosine kinases" Clinical Cancer Research May 1 2008
  • "Thrombophlebitis and cellulitis due to Campylobacter fetus ssp. fetus" Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries  1985
  • "PDGFRA activating mutations in gastrointestinal stromal tumors" Science January 31 2003
  • "A human gene coding for a membrane-associated nucleic acid-binding protein" Journal of Biological Chemistry October 27 2000

Additional information

Edit profile